Iryna Drozd Affimed ( NASDAQ: AFMD ) said it has received fast track designation from the FDA for its drug candidate AFM24 in combination with atezolizumab in the treatment of EGFR wild-type non-small cell lung cancer. AFM24 in combination with atezolizumab is currently being evaluated in a Phase 1/2 study for the treatment of EGFR wild-type and EGFR mutant advanced/metastatic non-small cell lung cancers, according to Affimed . Atezolizumab is marketed by Roche as Tecentriq.
More on Affimed Affimed N.V. (AFMD) Q4 2023 Earnings Call Transcript Affimed falls on 1-for-10 reverse stock split Seeking Alpha’s Quant Rating on Affimed Historical earnings data for Affimed Financial information for Affimed.